DEA agent to FDA safety panel: Hydrocodone combos are 'killing us'
This article was originally published in Scrip
Executive Summary
Drug safety advisers to the US FDA heard arguments from both ends of the spectrum on 24 January about the impact to patients and society if hydrocodone combination medicines, like Vicodin (acetaminophen-hydrocodone), are moved from Schedule III to the more restrictive Schedule II – or "up-scheduled" – under authorities granted to the agency by the 1970 US Controlled Substances Act (CSA).